[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RenJi Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":611},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,162,0,25,[9,54,75,112,139,159,185,209,231,255,273,295,323,343,366,389,414,439,457,475,493,513,536,561,587],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100645171","phase-2-the-safety-and-efficacy-of-upadacitinib-in-refractory-autoimmune-related-cholangitis-and-atopic-dermatitis-with-moderate-to-severe-itching-100645171",false,"NCT07678645","The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching","Evaluation of the Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis With Moderate to Severe Itching and Refractory Autoimmune Related Cholangitis: a Single Arm, Exploratory Clinical Study","Inclusion Criteria\n\nPatients must meet all of the following criteria to be eligible for enrollment:\n\n1. Aged ≥18 and ≤70 years, of either sex.\n2. Criteria for Atopic Dermatitis (AD)\n\n   Diagnosis of AD according to the Chinese diagnostic criteria for adult AD, defined as meeting the primary criterion (a) plus either criterion (b) or (c) below:\n   1. Presence of symmetrical eczema with a disease duration of more than 6 months.\n   2. Personal and\u002For first-degree family history of atopic diseases (e.g., eczema, allergic rhinitis, asthma, allergic conjunctivitis, etc.).\n   3. At least one of the following laboratory findings: elevated serum total immunoglobulin E (IgE), elevated peripheral blood eosinophil count, or positive allergen-specific IgE.\n\n   Presence of moderate-to-severe pruritus, defined as a Visual Analogue Scale (VAS) score ≥4.\n3. Criteria for Primary Biliary Cholangitis (PBC)\n\n   Diagnosis of PBC according to practice guideline criteria, defined as meeting at least two of the following three criteria:\n   1. Biochemical evidence of cholestasis, primarily elevated alkaline phosphatase (ALP) and\u002For gamma-glutamyl transferase (GGT).\n   2. Positivity for anti-mitochondrial antibody (AMA) or AMA-M2, or positivity for other disease-specific autoantibodies (anti-gp210 or anti-sp100 antibodies).\n   3. Histological evidence of non-suppurative destructive cholangitis and small bile duct destruction.\n\n   Patients must have received a standard regimen of ursodeoxycholic acid (UDCA) for ≥12 months (at a dose of no less than 13-15 mg\u002Fkg\u002Fday) in combination with at least two subsequent-line therapies (including Farnesoid X receptor agonists, peroxisome proliferator-activated receptor agonists, budesonide, or other immunosuppressants) for ≥3 months.\n\n   At screening, ALP ≥1.5 × upper limit of normal (ULN) or GGT ≥5 × ULN.\n4. Criteria for Primary Sclerosing Cholangitis (PSC)\n\nFor large-duct PSC, diagnosis must meet the following criteria:\n\n1. Biliary imaging showing characteristic multifocal, short-segmental, or annular strictures involving both intra- and extrahepatic bile ducts.\n2. At least one of the following clinical manifestations: biochemical evidence of cholestasis (primarily elevated ALP and\u002For GGT); clinical or histological evidence of coexisting inflammatory bowel disease (IBD); or liver histology showing periductal inflammation with fibrosis (i.e., periductal \"onion-skin\" appearance).\n3. Exclusion of secondary sclerosing cholangitis due to other etiologies.\n\nFor small-duct PSC, diagnosis must meet the following criteria:\n\n1. Biochemical evidence of cholestasis with no significant abnormalities on recent biliary imaging.\n2. Liver histology showing typical PSC changes as described above (periductal inflammation with fibrosis \u002F \"onion-skin\" appearance).\n3. Exclusion of other causes of cholestasis. Patients must have received a standard regimen of UDCA for ≥3 months (at a dose of no less than 13-15 mg\u002Fkg\u002Fday). At screening, ALP ≥1.5 × ULN or GGT ≥5 × ULN.\n\nExclusion Criteria\n\nPatients who meet any of the following criteria will be excluded from enrollment:\n\n1. Known concurrent or history of other hepatobiliary diseases, including but not limited to: active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; complete biliary obstruction; acute cholecystitis or symptomatic cholelithiasis; suspected or confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma.\n2. Child-Pugh Class C cirrhosis; evidence of end-stage liver disease, including: history of liver transplantation or being on the liver transplant waiting list; Model for End-Stage Liver Disease (MELD) score \\>20; severe portal hypertension complications (including severe gastric or esophageal varices, refractory or diuretic-resistant ascites, history of variceal bleeding); or other serious cirrhosis-related complications (spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome).\n3. Total bilirubin \\>10 × upper limit of normal (ULN).\n4. Serum creatinine ≥1.5 × ULN and creatinine clearance \\\u003C60 mL\u002Fmin.\n5. Platelet count \\\u003C50 × 10⁹\u002FL.\n6. International normalized ratio (INR) \\>1.5.\n7. Serum albumin \\\u003C3.0 g\u002FdL.\n8. Use of moderate or strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 14 days prior to the first dose of study drug or planned use throughout the study period.\n9. Presence of diseases that may cause non-hepatic elevation of ALP (e.g., Paget's disease of bone) or any condition with an anticipated life expectancy of less than 2 years.\n10. Known drug abuse or alcohol abuse within 6 months prior to the first dose of study drug, defined as weekly alcohol consumption exceeding 14 standard drinks (1 standard drink equivalent to 360 mL beer, 45 mL of 40% distilled spirits, or 150 mL wine).\n11. Unstable concomitant diseases or use of concomitant medications that cannot be maintained on a stable regimen throughout the clinical study period.\n12. Pregnant women, women planning to become pregnant, breastfeeding women, or fertile patients (male or female) who are unwilling to use at least one effective method of contraception from the time of signing informed consent until 30 days after the last dose of study drug.\n13. Participation in any other interventional clinical trial and receipt of any investigational product within 3 months prior to the first dose of study drug.\n14. Positive results for human immunodeficiency virus antibodies (HIV Ab) or Treponema pallidum antibodies (TP Ab).\n15. Any other condition that, in the investigator's judgment, would preclude the patient's participation in this study.","ALL","18 Years","70 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) represent the major autoimmune-driven entities within this category. Without effective intervention, these conditions may progress to liver failure and even death. Ursodeoxycholic acid (UDCA), the first-line therapy for PBC, has been shown to improve prognosis; however, 20%-40% of patients exhibit an inadequate biochemical response. For PSC, no clearly effective pharmacologic agent is currently available. In refractory patients, pruritus often progressively worsens, severely impairing quality of life and treatment adherence, underscoring an urgent need for novel therapeutic approaches that simultaneously address disease control and itch relief.\n\nAutoimmune-associated cholangitis frequently coexists with atopic dermatitis, and in a subset of patients, pruritus may be compounded by dermatologic factors. The pruritus of atopic dermatitis involves the JAK-STAT signaling pathway, which not only serves as a convergent node for pruritic signals but also constitutes a key downstream hub in the immune dysregulation characteristic of cholangitis. Inhibition of this pathway is therefore hypothesized to alleviate pruritus and modulate aberrant immune responses. Case reports have suggested that upadacitinib, a selective JAK inhibitor, may improve biochemical parameters in refractory PBC and exhibit potential anti-fibrotic effects.\n\nTo this end, investigators plan to conduct an exploratory clinical study to systematically evaluate the safety and efficacy of upadacitinib in patients with atopic dermatitis complicated by moderate-to-severe pruritus and refractory autoimmune-associated cholangitis.",[28,29,30],"Primary Biliary Cholangitis (PBC)","Primary Sclerosing Cholangitis (PSC)","Atopic Dermatitis (AD)",[28,29,30,32,33,34,35,36,37,38,39,40],"pruritus","upadacitinib","cholangitis","bile duct diseases","biliary tract diseases","Digestive System Diseases","Cirrhosis, Biliary","Cholangitis, Biliary","Cholangitis, Sclerosing","NOT_YET_RECRUITING","2026-06-30",{"date":44,"type":45},"2026-07-01","ACTUAL",{"date":47,"type":22},"2026-06-01",{"date":49,"type":22},"2028-05-31",{"name":51,"class":52},"RenJi Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":53},"100505232","early-phase-1-dual-target-car-t-cell-treatment-for-refractory-systemic-lupus-erythematosus-sle-patients-100505232","NCT05858684","Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients","Inclusion Criteria:\n\n1. 18-70 years old;\n2. Total score ≥ 10 on the EULAR\u002FACR 2019 SLE classification criteria;\n3. LLDAS response criteria are not achieved after administration with at least two immunosuppressants (including, but not limited to, azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, ciclosporin and iguratimod) and\u002For at least one approved biological agent for more than 6 months.\n4. SELENA-SLEDAI≥8;\n5. Patients with CD19+ B-cell;\n6. Hemoglobin≥85 g\u002FL;\n7. WBC≥2.5×10\\^9\u002FL\n8. NEUT≥1×10\\^9\u002FL;\n9. BPC≥50×10\\^9\u002FL;\n10. AST\u002FALT below 2 times the upper limit of normal; Creatinine clearance ≥30 mL\u002Fmin; blood bilirubin ≤2.0 mg\u002Fdl; echocardiography indicates that the ejection fraction is ≥50%;\n11. Adequate venous access for apheresis, and no other contraindications for leukapheresis;\n12. Women of childbearing age should have a negative serum or urine pregnancy test at screening and baseline. Subjects agree to take effective contraceptive measures during the trial until at least 1 year after CAR-T cells infusion.\n13. Agree to attend follow-up visits as required;\n14. Voluntary participation and informed consent signed by the patient or his\u002Fher legal\u002Fauthorized representative;\n\nExclusion Criteria:\n\n1. Renal disease: severe lupus nephritis (serum creatinine \\> 2.5 mg\u002FdL or 221 μmol\u002FL) within 8 weeks prior to leukapheresis, or subjects who need hemodialysis;\n2. CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident \\[CVA\\], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts;\n3. Patients with serious lesions and history of present illness of vital organs such as heart, liver, kidney and blood and endocrine system;\n4. Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers;\n5. Received immunosuppressive therapy within 1 week prior to leukapheresis;\n6. Patients with HIV infection; Active infection of hepatitis B virus or hepatitis C virus; Patients with syphilis infection;\n7. The presence or suspicion of an active fungal, bacterial, viral or other infection that cannot be controlled during screening;\n8. Received live vaccine treatment within 4 weeks prior to screening;\n9. Severe allergies or hypersensitivity;\n10. Contraindication to cyclophosphamide in combination with fludarabine;\n11. Subjects who have undergone major surgery within 2 weeks prior to signing the informed consent form, or who are scheduled to have surgery (other than local anesthetic surgery) during the trial or within 2 weeks of the infusion;\n12. cannula or drainage tubes other than central venous catheters;\n13. Pregnant or lactating women, or subjects who plan to have children within 1 year of treatment;\n14. Subjects with prior CD19 or BCMA-targeted therapy\n15. Participated in any clinical study within 3 months prior to enrollment\n16. Subjects with malignant tumour, except for Non-melanoma Skin Cancer with PFS\\>5yr; Cervical Cancer in situ; Bladder Cancer; Breast Cancer;\n17. Any situations that the investigator believes the patients are not suitable for the study.",{"count":61,"type":22},18,[63],"EARLY_PHASE1","This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.",[66],"CAR-T Cell Therapy","RECRUITING","2026-05-29",{"date":47,"type":45},{"date":71,"type":45},"2023-05-11",{"date":73,"type":22},"2029-06-10",{"name":51,"class":52},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":102,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":53},"100581542","phase-2-trop2-targeted-immunopet-imaging-of-solid-tumors-100581542","NCT06851663","Trop2-targeted immunoPET Imaging of Solid Tumors","Inclusion Criteria:\n\n* Aged 18-75 year-old and of either sex\n* Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","75 Years",{"count":83,"type":22},400,[25,85],"PHASE3","This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.",[88,89,90,91,92,93,94,95,96,97,98,99,100,101],"Solid Tumor","Solid Carcinoma","Uroepithelial Carcinoma","Bladder Cancer","Prostate Cancer","Lung Cancer","Nasopharyngeal Cancer","Liver Cancer","Cholangiocarcinoma","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","Thyroid Cancer","Head and Neck Cancer",[103,104,88],"Trophoblast cell surface antigen 2 (Trop2)","ImmunoPET","2026-05-27",{"date":68,"type":45},{"date":108,"type":45},"2024-12-23",{"date":110,"type":22},"2027-12",{"name":51,"class":52},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":53},"100641028","profunda-femoris-vein-thrombosis-evaluation-and-clearance-to-improve-outcomes-of-endovascular-treatment-for-acute-iliofemoral-deep-vein-thrombosis-100641028","NCT07622199","PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis","PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis: a Multicenter Randomized Controlled Study (The PROTECT Study)","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 85 years;\n2. Diagnosed with acute iliofemoral DVT involving iliac vein, common femoral vein, and PFV (confirmed by preoperative ultrasound, CT venography, or intraoperative venography);\n3. Time from symptom onset to endovascular treatment ≤ 14 days;\n4. Patient receives endovascular treatment with PMT;\n5. Patient provides written informed consent.\n\nExclusion Criteria:\n\n1. Presence of pre-existing PTS in the limb scheduled for treatment, or a history of symptomatic DVT in the same limb within the past 2 years;\n2. Concurrent symptomatic acute DVT involving the iliac vein and\u002For common femoral vein in the contralateral limb;\n3. Known allergy to heparin, low-molecular-weight heparin, contrast media, or other relevant agents;\n4. Concomitant severe pulmonary embolism with hemodynamic compromise, such as hypoxia or hypotension;\n5. Intolerance to endovascular intervention due to concurrent acute systemic illness, severe dyspnea, or other contraindications;\n6. Concomitant severe renal insufficiency with creatinine clearance \\\u003C 30 ml\u002Fmin;\n7. Presence of active bleeding, severe hepatic insufficiency, bleeding diathesis, or other coagulation disorders;\n8. Concomitant severe anemia (hemoglobin \\\u003C 8.0 mg\u002FdL) or thrombocytopenia (platelet count \\\u003C 80,000\u002FmL);\n9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;\n10. Pregnancy;\n11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency) with an estimated life expectancy \\\u003C 24 months;\n12. Participation in another clinical trial of a drug or medical device within the past 1 month that may interfere with the present study;\n13. Unwillingness to participate in this trial.","85 Years",{"count":121,"type":22},140,[123],"NA","Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS). The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein. Profunda femoris vein thrombosis clearance (PFV-TC) may improve the patency of iliofemoral vein and reduce the occurrence of PTS.",[126],"Deep Vein Thrombosis",[128,129,130,131],"Deep venous thrombosis","Percutaneous mechanical thrombectomy","Post-thrombotic syndrome","Profunda femoris vein","2026-05-26",{"date":134,"type":45},"2026-06-03",{"date":44,"type":22},{"date":137,"type":22},"2029-07-30",{"name":51,"class":52},{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":146,"targetDuration":148,"studyType":149,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":53},"100637538","comparison-of-different-mechanical-thrombectomy-devices-in-endovascular-treatment-of-acute-iliofemoral-venous-thrombosis-100637538","NCT07622212","Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis","Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)","Inclusion Criteria:\n\n1. Aged between 18 and 85 years;\n2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;\n3. Time from symptom onset to endovascular treatment ≤ 14 days;\n4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;\n5. Patients sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;\n2. Concurrent symptomatic acute DVT involving the iliac vein and\u002For common femoral vein in the contralateral limb;\n3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc.\n4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.\n5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.\n6. Concomitant severe renal insufficiency with creatinine clearance \\\u003C 30 ml\u002Fmin;\n7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.\n8. Concomitant severe anemia (hemoglobin \\\u003C 8.0 mg\u002FdL) or platelet count \\\u003C 80,000\u002FmL;\n9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;\n10. Pregnant women;\n11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy \\\u003C 24 months\n12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;\n13. Patients unwilling to participate in this trial.",{"count":147,"type":22},180,"24 Months","OBSERVATIONAL","A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.",[126],[128,129,130],{"date":134,"type":45},{"date":155,"type":45},"2024-01-01",{"date":157,"type":22},"2028-12-31",{"name":51,"class":52},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":53},"100637899","phase-2-hero-utuc-intravesical-rc48-after-rnu-for-her2-utuc-100637899","NCT07591805","HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC","A Prospective Phase II Study of Single Postoperative Intravesical Disitamab Vedotin to Prevent Bladder Recurrence After Radical Nephroureterectomy in HER2-Positive Upper Tract Urothelial Carcinoma","HERO-UTUC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically or radiologically suspected UTUC planned for RNU\n3. HER2-positive tumor defined as IHC 1+, 2+, or 3+ on preoperative or surgical specimen testing.\n4. ECOG performance status 0-1.\n5. No prior or concomitant bladder urothelial carcinoma within 5 years.\n6. Adequate hematologic, hepatic, and renal function.\n7. Ability to comply with protocol-required surveillance.\n8. Written informed consent. -\n\nExclusion Criteria:\n\n1.Evidence of metastatic disease before enrollment. 2.Prior treatment with disitamab vedotin. 3.Prior intravesical anti-cancer therapy within 12 months. 4.Active uncontrolled infection. 5.Pregnancy or breastfeeding. 6.Severe uncontrolled cardiovascular, pulmonary, hepatic, or systemic disease. 7.Known hypersensitivity to study drug components. 8.Any condition that, in the investigator's judgment, would compromise participation or interpretation.\n\n\\-",{"count":168,"type":22},49,[25],"This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU) in patients with HER2-positive upper tract urothelial carcinoma (UTUC). Eligible patients will receive one intravesical instillation of RC48 within 96 hours after surgery. The primary objective is to determine the 12-month intravesical recurrence rate. Serial urine samples will be prospectively collected to evaluate urinary methylation biomarkers for early recurrence detection.",[172],"Upper Urinary Tract Urothelial Carcinoma",[172,174,175,176],"Bladder Recurrence","Disitamab Vedotin","Radical Nephroureterectomy","2026-05-15",{"date":179,"type":45},"2026-05-18",{"date":181,"type":22},"2026-05-16",{"date":183,"type":22},"2028-01-31",{"name":51,"class":52},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":208,"locationsCount":4},"100637100","phase-2-neoadjuvant-pd-l1-inhibitor-plus-anlotinib-for-kidney-preservation-in-complex-renal-cell-carcinoma-100637100","NCT07602101","Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma","Neoadjuvant PD-L1 Blockade Combined With Anlotinib to Enable Nephron-Sparing Surgery in Patients With High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* • Age ≥18 years\n\n  * ECOG performance status 0-2\n  * Histologically confirmed clear cell renal cell carcinoma\n  * Clinical stage cT2-T3aN0M0 (AJCC 8th edition)\n  * RENAL nephrometry score ≥10\n  * Tumor assessed as requiring radical nephrectomy or complex partial nephrectomy\n  * Adequate organ function\n  * Signed informed consent\n\nExclusion Criteria:\n\n* • Prior systemic therapy for RCC (including ICIs or TKIs)\n\n  * Non-clear cell histology or sarcomatoid\u002Frhabdoid differentiation \\>20%\n  * Active autoimmune disease requiring systemic therapy\n  * Active uncontrolled infection (HBV\u002FHCV\u002FHIV)\n  * Prior organ transplantation\n  * Uncontrolled cardiovascular or pulmonary disease\n  * Pregnancy or breastfeeding",{"count":193,"type":22},33,[25],"This is a prospective, multicenter, single-arm phase II study evaluating the efficacy and safety of neoadjuvant PD-L1 inhibitor TQB2450 in combination with anlotinib in patients with locally advanced, high-complexity (RENAL score ≥10) clear cell renal cell carcinoma (ccRCC).\n\nThe primary objective is to determine whether neoadjuvant therapy can increase the rate of successful nephron-sparing surgery.\n\nIn addition, this study incorporates a pre-specified translational research platform including circulating tumor DNA (ctDNA) methylation-based minimal residual disease (MRD) monitoring, tumor multi-omics profiling, and radiomics analysis. Artificial intelligence-based models will be developed to predict treatment response and surgical conversion, enabling precision neoadjuvant strategies.",[197],"Clear Cell Renal Cell Carcinoma",[197,199,200,201,202],"Neoadjuvant Therapy","PD-L1","Anlotinib","Nephron-Sparing Surgery",{"date":204,"type":45},"2026-05-22",{"date":206,"type":22},"2026-05-31",{"date":157,"type":22},{"name":51,"class":52},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":53},"100623414","phase-2-neoadjuvant-ql1706-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer-100623414","NCT07396324","Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer","NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial","NEO-ITHRAN","Inclusion Criteria:\n\n* Aged ≥18 years\n* Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period",{"count":218,"type":22},55,[25],"This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer.",[222],"HR-positive\u002FHER2-negative Breast Cancer","2026-05-10",{"date":225,"type":45},"2026-05-13",{"date":227,"type":45},"2026-05-01",{"date":229,"type":22},"2031-12",{"name":51,"class":52},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":238,"minAge":18,"maxAge":19,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":53},"100614753","phase-2-neoadjuvant-serplulimab-plus-weekly-paclitaxel-and-carboplatin-in-tnbc-neo-serpent-100614753","NCT07283692","Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Female, Aged ≥18 and ≤70 years\n* Histologically confirmed triple negative breast cancer (ER\\\u003C10%, PR\\\u003C10%, and HER2 negative)\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period","FEMALE",{"count":240,"type":22},46,[25],"This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.",[244],"Triple Negative Breast Cancer",[246,247,248],"breast cancer","neoadjuvant","serplulimab",{"date":225,"type":45},{"date":251,"type":45},"2026-03-01",{"date":253,"type":22},"2031-09",{"name":51,"class":52},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":238,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":53},"100503178","rc48-adc-in-her2-low-advanced-breast-cancer-100503178","NCT05831878","RC48-ADC in HER2-low Advanced Breast Cancer","Disitamab Vedotin (RC48-ADC) in Patients With HER2-low Advanced Breast Cancer","Inclusion Criteria:\n\n* Female patients aged ≥18 years\n* Expected survival ≥12 weeks\n* ECOG 0-1\n* Histologically confirmed invasive advanced or metastatic breast cancer that is incurable and unresectable\n* At least one measurable lesion according to the RECIST 1.1\n* No history of antibody-drug conjugate use\n* Up to one previous chemotherapy for advanced disease\n* Available hormone receptor status. Hormone receptor-positive subjects are allowed to receive no more than two previous endocrine therapy for advanced disease\n* HER2-low tumors, defined as IHC1+ or IHC2+ with negative FISH test; or HER2-ultralow tumors, defined as incomplete and faint membrane staining in \\>0 but ≤10% of tumor cells\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of thromboembolic events\n* Uncontrolled systemic diseases, including diabetes, hypertension, interstitial lung disease, cirrhosis, etc.\n* Active infections requiring systemic treatment\n* Pregnant or lactating\n* Presence of brain metastases and\u002For carcinomatous meningitis",{"count":263,"type":22},36,[123],"To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.",[267],"Advanced Breast Cancer",{"date":225,"type":45},{"date":270,"type":45},"2023-05-04",{"date":110,"type":22},{"name":51,"class":52},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":294,"locationsCount":53},"100638386","phase-2-biomarker-enriched-kidney-preserving-strategy-with-disitamab-vedotin-plus-tislelizumab-in-her2-positive-high-risk-upper-tract-urothelial-carcinoma-100638386","NCT07584733","Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma","A Prospective, Multicentre, Single-Arm Phase II Study Evaluating a Response-Adapted Kidney-Preserving Strategy Using Neoadjuvant Disitamab Vedotin Plus Tislelizumab in Patients With HER2-Positive High-Risk Upper Tract Urothelial Carcinoma (DISTINCT-II)","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Histologically confirmed upper tract urothelial carcinoma (UTUC) arising from the renal pelvis or ureter, based on ureteroscopic biopsy.\n* High-risk UTUC, defined by at least one of the following features: Tumour size ≥2 cm; High-grade cytology or biopsy; Radiographic evidence of local invasion (≥cT2); Hydronephrosis; Multifocal disease\n* Clinical stage cT1-T3, N0-N1, M0, based on radiographic assessment.\n* N1 disease is permitted only if lymph nodes are considered resectable.\n* HER2-positive disease, defined as immunohistochemistry (IHC) score of 1+，2+ or 3+ on tumour tissue, assessed according to predefined criteria.\n* At least one measurable lesion according to RECIST version 1.1.\n* ECOG performance status of 0-1\n* Adequate organ function, including: Hematologic function; Hepatic function; Renal function (no strict upper\u002Flower limit required);\n* Patients must be considered potential candidates for a kidney-preserving treatment strategy, including: Absolute or relative indication for renal preservation (e.g., solitary kidney, baseline renal insufficiency), or Strong preference for kidney preservation after multidisciplinary discussion\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Evidence of distant metastatic disease (M1).\n* Unresectable or bulky nodal disease (≥N2) not amenable to curative-intent surgery.\n* Prior systemic therapy for urothelial carcinoma, including:Chemotherapy; Immunotherapy; HER2-targeted therapy.\n* Prior radical nephroureterectomy for current disease.\n* Active autoimmune disease requiring systemic treatment within the past 2 years.\n* Current use of immunosuppressive medication, excluding physiologic doses of corticosteroids.\n* Uncontrolled intercurrent illness, including but not limited to: Active infection requiring systemic therapy; Uncontrolled cardiovascular disease; Significant pulmonary disease\n* Known active hepatitis B, hepatitis C, or HIV infection with uncontrolled viral replication.\n* History of another malignancy within the past 5 years, except: Adequately treated basal cell carcinoma; Squamous cell skin cancer; In situ carcinoma.\n* Pregnant or breastfeeding women.\n* Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results.",{"count":281,"type":22},50,[25],"This is a prospective, multicentre, single-arm phase II study evaluating a response-adapted kidney-preserving strategy in patients with HER2-positive high-risk upper tract urothelial carcinoma (UTUC). Patients will receive neoadjuvant disitamab vedotin plus tislelizumab, followed by response-adapted local treatment, including kidney-sparing surgery or radical nephroureterectomy based on predefined criteria.\n\nThe primary objective is to assess whether this multimodal strategy can achieve clinically meaningful oncologic control while preserving renal function, as measured by 1-year kidney-intact event-free survival (KI-EFS). Secondary and exploratory objectives include evaluation of clinical response, survival outcomes, safety, renal function preservation, and longitudinal dynamics of circulating and urinary tumor DNA.",[285],"Upper Tract Urothelial Carcinoma",[287,288,175,289],"upper tract urothelial carcinoma","Kidney-Preserving","Tislelizumab","2026-05-07",{"date":225,"type":45},{"date":206,"type":22},{"date":157,"type":22},{"name":51,"class":52},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":315,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":53},"100581617","phase-2-cd70-targeted-immunopet-imaging-of-malignant-cancers-100581617","NCT06852638","CD70-targeted immunoPET Imaging of Malignant Cancers","CD70-targeted PET\u002F CT in the Diagnosis of Malignant Cancers","Inclusion Criteria:\n\n* Aged 18-80 year-old and of either sex；\n* Histologically confirmed diagnosis of renal cancer (especially ccRCC)\u002Flymphoma\u002FNPC or suspected renal cancer\u002Flymphoma\u002FNPC by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","80 Years",{"count":304,"type":22},300,[25],"This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.",[308,309,310,311,312,313,314],"Renal Cancer","Renal Clear Cell Carcinoma","Lymphoma","Lymphoma, Large B-Cell, Diffuse","Follicular Lymphoma","Mantle Cell Lymphoma","Nasopharyngeal Carcinoma",[316,104,308,310,314],"The cluster of differentiation (CD70)",{"date":318,"type":45},"2026-05-12",{"date":108,"type":45},{"date":321,"type":22},"2026-12-23",{"name":51,"class":52},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":53},"100641042","a-survey-on-growth-development-in-children-after-liver-transplantation-100641042","NCT07574398","A Survey on Growth Development in Children After Liver Transplantation","Longitudinal Study on Physical Growth in Children After Liver Transplantation","Inclusion Criteria:\n\n* Children with end-stage liver disease of various etiologies requiring liver transplantation.\n* Approved by the ethics committee, and written informed consent has been obtained from the parents\u002Flegal guardians.\n* Age ≤ 1 year (infancy).\n\nExclusion Criteria:\n\n* Age older than 1 year old.\n* Accept liver kidney combined transplantation surgery or second liver transplantation surgery.","1 Year",{"count":332,"type":22},275,"A single-center, large-sample, long-term longitudinal study was conducted to explore the trends and characteristics of changes in growth, development in pediatric liver transplant recipients, with the aim of guiding the development of intervention strategies and optimizing follow-up protocols.",[335],"Growth, Development in Pediatric Liver Transplant Recipients","2026-05-04",{"date":290,"type":45},{"date":339,"type":45},"2024-11-20",{"date":341,"type":22},"2029-12-31",{"name":51,"class":52},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":351,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100634287","eeg-tms-for-postoperative-delirium-after-cardiac-surgery-100634287","NCT07537725","EEG-TMS for Postoperative Delirium After Cardiac Surgery","Transcranial Magnetic Stimulation for Postoperative Delirium After Cardiac Surgery: A Prospective, Single-Center, Randomized Double-Blind Controlled Study","RECOVER-C","Inclusion Criteria:\n\n* Aged 50 years or older;\n* undergoing cardiac surgery with cardiopulmonary bypass (coronary artery bypass grafting, aortic valve replacement, mitral valve surgery, or combined procedures);\n* positive assessment by CAM-ICU postoperatively.\n\nExclusion Criteria:\n\n* Chronic antipsychotic treatment;\n* Receipt of antipsychotic medication before enrollment;\n* Patients with permanent loss of autonomy;\n* Not suitable for delirium assessment: including language disorder, deafness, blindness, aphasia, or coma;\n* Withdrawal of treatment or brain death;\n* Known pregnancy or breastfeeding;\n* Unable to provide consent according to national regulations;\n* Patients involuntarily hospitalized by regulatory authorities (compulsory measures);\n* Alcohol-induced delirium \u002F delirium tremens;\n* Contraindications to transcranial magnetic stimulation, including intracranial or cervical metal implants, history of brain surgery, history of epilepsy, cardiac pacemaker or implantable cardioverter-defibrillator, cochlear implant, known intracranial space-occupying lesions, cardiac pacemaker implantation, recent stroke (\\\u003C3 months);\n* Acute infectious diseases;\n* Preoperative severe hemodynamic instability (e.g., requiring intra-aortic balloon pump or extracorporeal membrane oxygenation support).","50 Years",{"count":353,"type":22},144,[123],"This is a prospective, single-center, randomized, double-blind, sham-controlled trial evaluating the safety and efficacy of transcranial magnetic stimulation (TMS) for the treatment of postoperative delirium in patients undergoing cardiac surgery with extracorporeal circulation. Eligible patients aged 50 years or older who develop delirium after surgery, as assessed by the CAM-ICU, will be randomized to receive either active TMS or sham stimulation. The intervention consists of three daily cycles of intermittent and continuous theta burst stimulation over five days. The primary outcome is the duration of delirium within the five-day intervention period. Secondary outcomes include delirium severity, time to successful discharge, and survival at 30 and 90 days. A total of 144 participants will be enrolled.",[357],"Delirium","2026-04-13",{"date":360,"type":45},"2026-04-17",{"date":362,"type":22},"2026-04-27",{"date":364,"type":22},"2027-03-31",{"name":51,"class":52},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":53},"100627612","retrospective-analysis-of-acute-pancreatitis-after-percutaneous-mechanical-thrombectomy-in-treatment-of-thrombotic-disorders-100627612","NCT07450898","Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders","Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders (The RATIO Study)","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Patients with thrombotic peripheral vascular diseases treated by percutaneous mechanical thrombectomy;\n* Patients developed acute pancreatitis within 14 days after percutaneous mechanical thrombectomy;\n* Patients with written informed consent.\n\nExclusion Criteria:\n\n* Patients with acute pancreatitis attributed to other confirmed causes;\n* Patients unable or unwilling to participate in the study.",{"count":374,"type":22},10,"Acute pancreatitis is a rare complication after percutaneous mechanical thrombectomy in treatment of thrombotic disorders. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient\u002Fprocedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.",[377,378],"Acute Pancreatitis (AP)","Thrombotic Disorders",[380],"Thrombectomy","2026-03-03",{"date":383,"type":45},"2026-03-05",{"date":385,"type":45},"2016-01-01",{"date":387,"type":22},"2026-12-31",{"name":51,"class":52},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":396,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":53},"100627527","biochemical-response-and-clinical-outcomes-in-patients-with-pbc-100627527","NCT07449793","Biochemical Response and Clinical Outcomes in Patients With PBC","Impact of Enhanced Biochemical Response on Clinical Outcomes in Patients With Primary Biliary Cholangitis: A Bidirectional Cohort Study","Inclusion Criteria:\n\n* Age above 18 years old, Male or Female,\n* Diagnosis of PBC meeting the 2018 American Association for the Study of Liver Diseases (AASLD) Practice Guidelines criteria;\n* Treatment with UDCA at a standard dose (13-15 mg\u002Fkg\u002Fday), with or without other second-line medications.\n\nExclusion Criteria:\n\n* Co-existing liver diseases, including but not limited to: Hepatitis C virus infection; Active Hepatitis B infection (patients who are HBsAg-negative and HBeAg-negative may be considered eligible per investigator assessment);\n* Autoimmune Hepatitis (AIH); Primary Sclerosing Cholangitis (PSC); Suspected or confirmed hepatocellular carcinoma;\n* Female subjects who is pregnant or breastfeeding during the study;\n* History of other malignancies, including hematological tumors, solid tumors except hepatobiliary system;\n* Poor adherence or inability to complete the study follow-up.",{"count":397,"type":22},3000,"This study is a bidirectional cohort study. The investigators conduct a bidirectional cohort study utilizing a database in mainland China, continuously collecting demographics, clinical symptoms, and biochemical characteristics of diagnosed PBC patients.\n\nThe study aims to analyze the association between varying post-treatment alkaline phosphatase (AKP) levels and complication-free survival rates, with the objective to develop and validate a predictive survival model.",[28,400],"Primary Biliary Cholangitis",[402,403,404,405,37,39,38,406],"Primary Biliary Cirrhosis","Cholangitis","Bile Duct Diseases","Biliary Tract Diseases","Chronic Nonsuppurative Destructive Cholangitis","2026-02-26",{"date":409,"type":45},"2026-03-04",{"date":411,"type":22},"2026-02-01",{"date":183,"type":22},{"name":51,"class":52},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":437,"locationsCount":438},"100543618","safety-and-efficacy-of-ventricular-irrigation-for-ventriculitis-100543618","NCT06358209","Safety and Efficacy of Ventricular Irrigation for Ventriculitis","Safety and Efficacy of Ventricular Irrigation for Ventriculitis: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-65 years old;\n* CSF is purulent (it appears cloudy or yellow) and white blood cell count over 1000×10\\^6\u002FL.\n* Fever (\\>38.0°C)\n* Meet at least one of the following: 1. Patient has organism(s) identified from CSF by a culture or non-culture based microbiologic testing method; 2. Cranial CT or MRI indicating intraventricular floccule or pus.\n* With consent form\n\nExclusion Criteria:\n\n* With GCS score of 3\n* With unstable vital signs such as no spontaneous breathing and blood pressure maintenance drugs\n* With severe propensity for bleeding (Such as coagulation dysfunction, active bleeding, etc.), and unable to tolerate the surgical procedures or operations related to ventricular irrigation treatment.\n* Pregnant or lactating women","65 Years",{"count":423,"type":22},310,[123],"Ventriculitis is a severe infectious disease of the central nervous system with diverse etiologies. Currently, the treatment for ventriculitis is challenging, with poor prognosis. The mortality rate of ventriculitis is generally reported to be higher than 30%, with the highest reaching over 75%. Even among survivors, over 60% suffer from a variety of neurological sequelae, including cognitive impairment, gait disturbances, paralysis, behavioral disorders, and epilepsy.\n\nCurrently, treatments for ventriculitis recommended by guidelines primarily focus on the selection and administration of antibiotics, while the effects of surgical interventions have not been fully elucidated. In recent years, several studies have explored the use of ventricular irrigation in ventriculitis, indicating that ventricular irrigation techniques may accelerate the control of ventricular infection, mitigate damage to the central nervous system caused by infections, improve the prognosis of ventriculitis, and reduce complications such as hydrocephalus. However, current studies are still relatively scarce, and mostly case reports and retrospective studies. High-quality evidence is still lacking for the application of ventricular irrigation in ventriculitis.\n\nThis multicenter randomized controlled trial aims to explore the safety and effectiveness of ventricular irrigation compared to conventional treatment for ventriculitis, analyze the effectiveness of ventricular irrigation across different pathogen subgroups, and investigate independent risk factors for different prognostic states in patients with ventriculitis.",[427],"Central Nervous System Infections",[429,430],"Ventriculitis","Ventricular irrigation","2026-02-23",{"date":433,"type":45},"2026-02-25",{"date":435,"type":45},"2025-07-01",{"date":157,"type":22},{"name":51,"class":52},35,{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":446,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":448,"conditions":449,"keywords":450,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":53},"100525671","comparison-of-percutaneous-mechanical-thrombectomy-with-different-access-in-treatment-of-acute-deep-venous-thrombosis-100525671","NCT06124768","Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis","Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis (The CODA Study)","Inclusion Criteria:\n\n1. Age between 18-85 years old;\n2. Acute DVT occurred no more than 14 days since the onset of disease;\n3. DVT treated by percutaneous mechanical thrombectomy\n4. Informed consent signed by patients.\n\nExclusion Criteria:\n\n1. Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;\n2. Women during pregnancy and lactation;\n3. Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\\\u003C6 months);\n4. Patients who are unable or unwilling to participate in the study.",{"count":447,"type":22},210,"The study aims to compare the modified approach through ipsilateral deep calf venous access or contralateral femoral venous access with the traditional approach through ipsilateral popliteal venous access for iliofemoral deep venous thrombosis (DVT) with distal popliteal vein thrombosis, and determine whether it can achieve similar therapeutic effects as iliofemoral DVT without distal popliteal vein thrombosis.",[126],[128,129,130],{"date":433,"type":45},{"date":453,"type":45},"2021-01-01",{"date":455,"type":22},"2027-10-31",{"name":51,"class":52},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":53},"100539253","dalpiciclib-in-hrher2--abc-100539253","NCT06301438","Dalpiciclib in HR+\u002FHER2- ABC","Efficacy and Safety of Dalpiciclib in HR+\u002FHER2- Advanced Breast Cancer: a Real-world Study","Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer\n* Hormone receptor-positive and human epidermal growth factor receptor 2-negative\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* History of immunodeficiency",{"count":465,"type":22},103,"To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive\u002FHER2-positive advanced breast cancer.",[267],{"date":469,"type":45},"2026-02-03",{"date":471,"type":45},"2024-05-03",{"date":473,"type":22},"2028-12",{"name":51,"class":52},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":238,"minAge":18,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":53},"100487014","pre-operative-therapy-in-breast-cancer-100487014","NCT05621564","Pre-operative Therapy in Breast Cancer","The Effect of Pre-operative Therapy on Response and Survival in Breast Cancer","Inclusion Criteria:\n\n* Female, Aged ≥18 years\n* Histologically confirmed primary breast cancer\n* Plan to receive pre-operative therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of neurological or psychological disease, including epilepsy or dementia\n* Not suitable to participate in this study judged by investigators",{"count":483,"type":22},488,"This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.",[486],"Breast Cancer",{"date":469,"type":45},{"date":489,"type":45},"2022-11-01",{"date":491,"type":22},"2030-11",{"name":51,"class":52},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":238,"minAge":18,"maxAge":19,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":53},"100466941","ctcs-in-breast-cancer-after-neoadjuvant-treatment-and-surgery-a-multicenter-prospective-clinical-trial-100466941","NCT05360290","CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial","The Value of Circulating Tumor Cells in Patients With Breast Cancer Who Completed Surgery After Neoadjuvant Treatment: a Multicenter, Prospective Clinical Trial","CTCNeoBC-E","Inclusion Criteria:\n\n* Female, aged ≥18 and ≤70 years;\n* Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);\n* Completed neoadjuvant treamtment and surgery (within 4 years after surgery);\n* Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV);\n* Female patients who are pregnancy or lactation;\n* Uncontrollable puncture site infection or systemic infection;",{"count":502,"type":22},484,[123],"The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.",[486,506],"Circulating Tumor Cell",{"date":469,"type":45},{"date":509,"type":45},"2022-09-14",{"date":511,"type":22},"2029-06",{"name":51,"class":52},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":53},"100623139","feasibility-study-of-diaphragm-synchronized-pacing-dsp-via-the-left-inferior-phrenic-vein-lipv-approach-100623139","NCT07392749","Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach","Inclusion Criteria:\n\n* Patients aged \\>=18 yrs;\n* Patients indicated for CRT or CRT-D , planned for LV lead implantation;\n* Patients are willing to participate in the study and provide signed informed consent\n\nExclusion Criteria:\n\n* CRT or CRT-D replacement\n* Ischemic heart disease with CABG history\n* Diaphragm dysfunction history\n* Phrenic nerve injury\n* IVC filter history\n* Abdominal surgery history\n* Splenomegaly\n* Pulmonary disease\n* Moderate or severe liver cirrhosis\n* Severe hepatic or renal dysfunction\n* Currently pregnant or planning pregnancy during the study period\n* Patients participate in another study that will confound this study",{"count":374,"type":22},[123],"Cardiac resynchronization therapy（CRT） benefits a portion of patients, while more patients are not yet indicated to a therapy that mechanically helps the heart systole and\u002For diastole. Synchronized diaphragmatic pacing may be feasible to induce diaphragm local contraction and recoil that enhance pump function of the heart, thus improve cardiac function and QoL.\n\nThis acute, interventional study is conducted in a single site, Renji Hospital, to evaluate the feasibility of diaphragm pacing and assess the beneficial effect of pacing-regulated diaphragm movement to the heart, with 10 cases of sample size and one-week follow-up after discharge.",[523],"Heart Failure",[525,526,527],"CRT","CRT-D","DSP","2026-01-29",{"date":530,"type":45},"2026-02-06",{"date":532,"type":45},"2025-11-28",{"date":534,"type":22},"2026-03-31",{"name":51,"class":52},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":544,"briefSummary":545,"conditions":546,"keywords":551,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":4},"100619319","efficacy-of-immediate-versus-staged-complete-revascularization-in-patients-with-nste-acs-and-multivessel-disease-future-ii-100619319","NCT07343076","Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)","Inclusion Criteria:\n\n1. Age: 18 years or older.\n2. Patients with intermediate-to-high risk NSTE-ACS who meet the diagnostic criteria specified in current guideline, complicated by multivessel coronary artery disease, and have successfully undergone PCI for the culprit vessel.\n3. PCI within 72 hours of diagnosis.\n4. Accompanied by multivessel disease: defined as at least one non-culprit artery that meets the following conditions: a diameter of ≥2.5 mm by visual inspection, which can be successfully subjected to PCI, and the most severe diameter stenosis rate by visual inspection is at least 70% or positive coronary physiology testing.\n5. Sign an informed consent form before participating in the study.\n\nExclusion Criteria:\n\n1. Have received thrombolytic treatment.\n2. Cardiogenic shock or SBP\\\u003C 90 mmHg.\n3. Patients in whom the culprit vessel cannot be clearly identified.\n4. Left main coronary artery lesion, non-infarct-related arteries are CTO lesions or severely calcified lesions, complex lesions that require the use of special devices such as rotational ablation\u002Flaser.\n5. Previous PCI within the past 1 month or previous coronary artery bypass graft (CABG).\n6. Accompanied by other diseases that lead to an expected survival time of ≤ 12 months.\n7. Patients with other serious diseases such as severe renal insufficiency (creatinine clearance value \\\u003C30ml\u002Fmin), hepatic insufficiency, thrombocytopenia (≤50\\*109\u002FL).\n8. Patients with severe valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension.\n9. Not suitable for clinical study:\n\n   1. Have enrolled in the other clinical studies that may affect the outcome assessment of this study.\n   2. Pregnant and lactating women.\n   3. Known allergy to the drugs that may be used in the study.\n   4. Unable to comply with the trial protocol or follow-up requirements; or the investigator believes that participation in the trial may put the patient at greater risk.",{"count":543,"type":22},1904,[123],"This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD).\n\nNSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form:\n\nIntervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing).\n\nControl group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.",[547,548,549,550],"NSTEMI","NSTEMI - Non-ST Segment Elevation MI","Non-ST-elevation Acute Coronary Syndrome","NSTE-ACS (NSTEMI and UA)",[547,552],"FUTURE II","2026-01-28",{"date":555,"type":45},"2026-01-30",{"date":557,"type":22},"2026-02-28",{"date":559,"type":22},"2031-02-28",{"name":51,"class":52},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":238,"minAge":18,"maxAge":81,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":53},"100571098","phase-1-target-specific-immunopet-imaging-of-breast-cancer-100571098","NCT06715826","Target-specific immunoPET Imaging of Breast Cancer","Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years old and of female gender；\n2. Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.",{"count":569,"type":22},200,[571,25],"PHASE1","The aim of this study is to establish and optimize the Trop2\u002FHER2-targeted PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.",[486,574,575],"Breast Neoplasms","Breast Cancer Metastatic",[577,578,486,104],"Trop2","HER2","2026-01-25",{"date":581,"type":45},"2026-01-27",{"date":583,"type":45},"2024-09-21",{"date":585,"type":22},"2026-11",{"name":51,"class":52},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":53},"100618767","a-clinical-study-using-fapi-pet-imaging-to-assess-the-postoperative-effects-of-tavi-in-patients-with-aortic-stenosis-100618767","NCT07335900","A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","A Clinical Study Using FAPI-PET Imaging to Evaluate the Effects of TAVI on Reversing Myocardial Structural and Functional Remodeling in Patients With Aortic Stenosis","Inclusion Criteria:\n\n① Age 18 years or older, any gender; ② Confirmed diagnosis of severe degenerative aortic stenosis by echocardiography (valve area AVA \\\u003C 1.0 cm² or mean transvalvular gradient \\> 40 mmHg; for AS with reduced ejection fraction and low-flow, low-gradient, the presence of outflow tract reserve must be confirmed with dobutamine stress); ③ Evaluated by the heart team as unsuitable for surgical open-heart valve replacement due to advanced age or severe comorbidities, without anatomical contraindications, and expected to benefit from transcatheter valve implantation. Patients who meet these criteria and decide to undergo TAVI will be assigned to the TAVI group; those who meet the criteria but do not undergo valve replacement will enter the control group (possible scenarios include: relatively mild valve stenosis not meeting TAVI indication, or patient refusal of surgery, opting for drug therapy only, etc.).\n\nExclusion Criteria:\n\n* Recent acute myocardial infarction (less than 1 month from onset to enrollment) or the presence of active myocarditis, infectious endocarditis, and other acute inflammatory conditions, as these conditions can significantly affect FAPI uptake and cardiac function; ② History of old myocardial infarction (with existing myocardial scarring and remodeling, which affect fibroblast imaging); ③ Presence of uncontrolled severe arrhythmias, such as persistent ventricular tachycardia, ventricular fibrillation, or high-risk second-degree or higher atrioventricular block, resulting in hemodynamic instability due to arrhythmia within the past 3 months; ④ Concomitant severe cardiovascular diseases affecting study evaluation, including severe valvular disease (excluding AS, such as severe mitral regurgitation), hypertrophic obstructive cardiomyopathy, primary pulmonary hypertension, etc.; ⑤ Presence of examination contraindications: allergy to PET tracers or MRI contrast agents, severe renal insufficiency (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²) with inability to tolerate gadolinium-enhanced MRI, or severe claustrophobia preventing compliance with imaging examinations; ⑥ Allergic constitution (history of allergy to multiple drugs or unknown substances); ⑦ Pregnant or breastfeeding women (female subjects of childbearing potential must provide a negative pregnancy test before enrollment and use effective contraception during the study); ⑧ Any other situation that the investigator believes could significantly increase study risk or interfere with result interpretation, such as active malignant tumors or advanced disease with expected survival of less than 1 year; ⑨ Inability to comply with the trial protocol or follow-up requirements (e.g., poor prior adherence, expected inability to attend scheduled follow-ups).",{"count":7,"type":22},[123],"This study will include patients with severe degenerative aortic stenosis (AS) who meet the inclusion criteria and voluntarily participate (planned to undergo TAVI), as well as patients with aortic stenosis who have not undergone valve replacement (control group). All enrolled patients will undergo a \\^18F-FAPI-1801 PET\u002FCT scan at baseline (before or at the time of TAVI) and 6 months postoperatively to quantitatively evaluate myocardial fibroblast activation and structural remodeling indicators, and to follow up on changes in clinical cardiac function. Patients with aortic stenosis receiving only medical therapy will be set as the control group for comparative analysis, to assess the impact of relieving aortic stenosis on the reduction of myocardial fibrosis activity, myocardial remodeling, and reversal of cardiac function.",[598],"Severe Aortic Valve Stenosis",[600,601,602],"Severe aortic valve stenosis","Transcatheter Aortic Valve Replacement","FAPI-PET","2026-01-12",{"date":605,"type":45},"2026-01-13",{"date":607,"type":22},"2025-12-19",{"date":609,"type":22},"2027-05-30",{"name":51,"class":52},""]